If I could interject, I've seen the SEC investigate other
If I could interject, I've seen the SEC investigate other penny stock scams. It can get expensive and litigation can take years. The SEC has to go through the judicial system just like anyone else--as it should, but that can take time.
I think the onus is on investors to make better decisions. Even if investors made it a practice to ask some basic questions about the value-add, that would probably have prevented this company from ever getting a foothold.
I think the SEC did a great job here--they identified the accounting fraud and showed that the founder was highly dishonest...and did so at what was certainly a minimal cost. Any investors who paid attention saved themselves an additional 95% loss in the stock. Those here who tried to instead turn the tables by crying that the SEC was dishonest, found themselves holding the proverbial bag.
Plastic2Oil, Inc. (PTOI) Stock Research Links
Yes, I understand your penny stock also is the real deal, created with the inventiveness of Edison and destined to be the next Microsoft. Yes, I understand that the delays are also only because your company is making their product and/or technology even more revolutionary.
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
Papa John’s $2.7 Billion Takeover Bid: Insights into Potential Value Recently, shares of Papa John’s International Inc (NASDAQ:PZZA) experienced a notable surge, leading to a halt in trading due to high volatility. This surprising movement came in light of credible reports suggesting a take-private cash offer of $65 per share from TriArtisan Capital Advisors, totaling...
Continue Reading
Octopus Apollo VCT plc AGM Results Overview Octopus Apollo VCT plc recently conducted its Annual General Meeting (AGM), showcasing significant engagement from shareholders. The meeting aimed to discuss key resolutions impacting the future direction of the company. Voting Outcomes of the AGM The company disclosed that all resolutions were successfully passed during the...
Continue Reading
Carisma Therapeutics Showcases Strong Financial Performance Carisma Therapeutics Inc. (NASDAQ: CARM), a clinical-stage biopharmaceutical company, recently released its financial performance for the third quarter of 2024. With a focus on developing innovative immunotherapies, Carisma provided insight into its ongoing projects. Key Developments and Milestones Carisma's...
Continue Reading
Overview of the Epinephrine Market The global epinephrine market is on a significant upswing, with recent evaluations estimating its value at USD 3.11 billion and a projected growth to approximately USD 6.39 billion within the next decade. As a critical hormone and neurotransmitter produced by the adrenal glands, epinephrine is essential in treating severe allergic...
Continue Reading
Canadian North Resources Makes Significant Progress in Operational Strategy Highlights: Canadian North has expanded its bio-metallurgical programs significantly, achieving impressive nickel and cobalt extraction rates through innovative bio-leaching tests. The focus remains on extracting copper and other precious group elements (PGE) metals from the Ferguson Lake Project....
Continue Reading